Citadel Advisors
NAGE

Citadel Advisors’s Niagen Bioscience NAGE Stock Holding History

Citadel Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Buy
630,109
+99,632
+19% +$404K ﹤0.01% 6541
2026
Q1 		$2.34M Buy
530,477
+138,937
+35% +$750K ﹤0.01% 5756
2025
Q4 		$2.49M Buy
391,540
+192,237
+96% +$1.34M ﹤0.01% 5513
2025
Q3 		$1.86M Buy
+199,303
New +$2.01M ﹤0.01% 6224
2025
Q2 		– Sell
-106,899
Closed -$1.06M – 15722
2025
Q1 		$738K Buy
106,899
+80,284
+302% +$504K ﹤0.01% 7625
2024
Q4 		$141K Buy
26,615
+26,313
+8,713% +$144K ﹤0.01% 10983
2024
Q3 		$1.1K Sell
302
-9,650
-97% -$30.4K ﹤0.01% 13900
2024
Q2 		$27.2K Sell
9,952
-31,081
-76% -$104K ﹤0.01% 12363
2024
Q1 		$143K Sell
41,033
-138,662
-77% -$257K ﹤0.01% 10832
2023
Q4 		$257K Buy
179,695
+6,925
+4% +$9.65K ﹤0.01% 9472
2023
Q3 		$252K Sell
172,770
-14,443
-8% -$22.6K ﹤0.01% 9486
2023
Q2 		$294K Sell
187,213
-22,779
-11% -$34K ﹤0.01% 9095
2023
Q1 		$321K Buy
209,992
+59,701
+40% +$106K ﹤0.01% 9238
2022
Q4 		$252K Buy
150,291
+93,726
+166% +$149K ﹤0.01% 9679
2022
Q3 		$70K Sell
56,565
-316,992
-85% -$510K ﹤0.01% 11393
2022
Q2 		$623K Buy
373,557
+264,478
+242% +$517K ﹤0.01% 8159
2022
Q1 		$268K Sell
109,079
-38,144
-26% -$104K ﹤0.01% 10844
2021
Q4 		$551K Buy
147,223
+112,257
+321% +$606K ﹤0.01% 9459
2021
Q3 		$219K Buy
34,966
+5,740
+20% +$47.3K ﹤0.01% 11804
2021
Q2 		$288K Sell
29,226
-44,081
-60% -$384K ﹤0.01% 11372
2021
Q1 		$685K Buy
+73,307
New +$581K ﹤0.01% 8992
2020
Q3 		– Sell
-29,704
Closed -$137K – 10874
2020
Q2 		$137K Sell
29,704
-43,751
-60% -$196K ﹤0.01% 8803
2020
Q1 		$239K Buy
+73,455
New +$282K ﹤0.01% 7711
2019
Q1 		– Sell
-21,050
Closed -$72K – 9986
2018
Q4 		$72K Sell
21,050
-23,286
-53% -$80.9K ﹤0.01% 8385
2018
Q3 		$190K Buy
44,336
+27,315
+160% +$117K ﹤0.01% 8247
2018
Q2 		$63K Sell
17,021
-42,319
-71% -$161K ﹤0.01% 8392
2018
Q1 		$249K Buy
+59,340
New +$311K ﹤0.01% 7018

Other funds holding NAGE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citadel Advisors's NAGE Position: Q2 2026 in Review

Citadel Advisors increased its Niagen Bioscience (NAGE) stake by 19% in Q2 2026, buying an estimated $404K and bringing the position to 630,109 shares worth $2.01M. The position accounts for ﹤0.01% of the portfolio, ranked #6541.

Citadel Advisors first reported a position in NAGE in Q1 2018 and has held it in 27 quarters since. The position peaked at $2.49M in Q4 2025. 140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

  • Citadel Advisors held 630,109 shares of Niagen Bioscience worth $2.01M as of Q2 2026.
  • Citadel Advisors bought 99,632 Niagen Bioscience shares in Q2 2026, an estimated $404K.
  • Niagen Bioscience made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #6541 holding.
  • Citadel Advisors first reported a position in Niagen Bioscience in Q1 2018 and has held it in 27 quarters since.
  • Citadel Advisors's Niagen Bioscience position peaked at $2.49M in Q4 2025.
  • 140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.